Eight weeks of supplementation with Ixoreal Biomed’s SRI-81 Shatavari was also associated with improvements in measures of fatigue and vigor, according to findings published in the International Journal of Women’s Health.
The study’s findings were welcomed by Kartikeya Baldwa, CEO of Ixoreal Biomed Inc. “Perimenopause affects women across multiple domains simultaneously, including vasomotor symptoms, stress, mood, and quality of life,” he said. “In this trial, SRI-81 produced significant improvements in several of these areas at a dose of 300 mg once daily. This provides clinical support for standardized, root-only Shatavari in women’s health formulations.”
Ayurvedic traditional use
Dubbed the “Queen of Herbs”, Shatavari (Asparagus racemosus) has a long history in Ayurveda. The herb is reported to contain phytoestrogens, compounds known for their weak estrogen-like effects. Previous studies have found that shatavarins, key phyto-actives in shatavari, may interact with estrogen receptors.
According to a 2024 paper in Bioinformation, “Shatavari is an important Ayurvedic herb that has several bioactive phytoconstituents such as various shatavarins which have high molecular weights and large structures.
“The effects of shatavari are well-known in improving female health conditions. Shatavari is known to manage and improve female reproductive health, managing symptoms of menopause, antioxidant effect, anti-anxiety effect, helps in proper lactation and other female health-related aspects,” wrote scientists from Jawaharlal Nehru Technological University-Hyderabad in India.
SRI-81 Shatavari is standardized to Shatavarin IV as well as total shatavarins and is designed to provide science-backed support for women seeking natural solutions during the menopausal transition. The ingredient was launched at SupplySide Global 2025 in Las Vegas.
Study details
The prospective, randomized, double-blind, placebo-controlled study included 80 perimenopausal women aged between 40 and 55. Researchers from Tieten Medi City Hospital and the D.Y. Patil University of School and Medicine randomly assigned the women to receive either 300 mg per day of SRI-81 Shatavari root extract or a placebo for eight weeks.
Data from the 73 women who completed the study showed that shatavari supplementation was associated with significant improvements in menopausal symptom scores on the Menopause Rating Scale, compared to placebo. The MRS assesses complaints across three domains, including somatic-vegetative (hot flashes, heart discomfort, sleep problems, and joint or muscle pain), psychological (mood, irritability, anxiety, and fatigue), and urogenital (sexual problems, bladder issues, and vaginal dryness).
Specifically, the total MRS scores decreased by 42.6% from baseline in the shatavari group, compared to a 5.5% reduction in the placebo group.
Moreover, perceived stress scores declined by almost 30% compared to baseline in the SRI-81 group, while hot-flash scores decreased by 26% with SRI-81, compared to only 7% in the placebo group.
Importantly, no adverse events were reported during the trial. Liver and kidney function markers remained stable throughout the eight weeks.
“The present results provide novel evidence that Shatavari root extract may be particularly effective during this transitional phase, where symptom variability is greatest,” wrote the researchers. “While some of these benefits may also extend into the postmenopausal period, stating that trials in menopausal women are needed to establish its efficacy beyond the perimenopausal population.”
Source: International Journal of Women’s Health. 17:4057–4073. doi: 10.2147/IJWH.S544267. “Efficacy and Safety of Shatavari (Asparagus racemosus) Root Extract for Perimenopause: Randomized, Double-Blind, Placebo-Controlled Study”. Authors: S. Mahajan, et al.
